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periods of starvation. However, an increased rate of lipolysis 
and plasma FFA concentrations can cause multi-organ in-
sulin resistance (1). In contrast, an increased capacity of 
adipocytes to produce FFAs from glucose (i.e., de novo lipo-
genesis) is associated with insulin sensitivity (2–4). Exces-
sive accumulation of triglycerides in adipose tissue, which 
occurs in people with obesity, is associated with metabolic 
abnormalities and diseases, including insulin resistance, 
atherogenic dyslipidemia, nonalcoholic fatty liver dis-
ease, and type 2 diabetes (5). These findings underscore 
the importance of the balance between adipocyte triglycer-
ide lipolysis and synthesis in regulating body fat mass and 
metabolic health.
For adipocytes to store lipid, FAs are sequentially esteri-
fied to a glycerol backbone to synthesize the primary form 
of stored energy, triglyceride. There are two major path-
ways for triglyceride synthesis. The canonical pathway for 
FA incorporation of triglyceride begins with glycerol-
3-phosphate and through sequential acylation and de-
phosphorylation of the glycerol backbone, triglyceride is 
formed. Deficiencies in specific steps in this pathway are 
known to result in lipodystrophy and failure of adipocytes 
to terminally differentiate (6). The other pathway of tri-
glyceride synthesis involves the acylation of monoacylg-
lycerol (MG) by monoacylglycerol acyltransferase (MGAT) 
enzymes to form diacylglycerol (DG) (6). Relative to the 
glycerol-3-phosphate pathway, the role of the MGAT path-
way in contributing to adipocyte lipogenesis and lipid 
metabolism is much less well understood. Three related 
MGAT-encoding genes have been identified in humans; 
namely, MOGAT1, MOGAT2, and MOGAT3, which en-
code MGAT1, MGAT2, and MGAT3. In mice, Mogat1  
and Mogat2 encode MGAT1 and MGAT2, but the mouse 
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Mogat3 is a pseudogene and not analogous to human 
MOGAT3 (7–9). Data from a series of studies have shown 
that MGAT2 is important for enterocyte absorption of 
ingested fat (7, 10–12). MGAT1 is not well-expressed in 
intestine, but MGAT1-mediated MGAT activity may be 
important in the pathogenesis of obesity-related hepatic 
insulin resistance (13–15). Some recent work using MGAT1 
constitutive knockout mice has called into question 
whether MGAT1 is a significant contributor to tissue MGAT 
activity (16). However, acute knockdown of MGAT1 in ste-
atotic liver reduced MGAT activity and promoted an insu-
lin-sensitive phenotype (13). Other than in intestine and 
liver, the metabolic effects of MGAT enzymes have been 
little studied. For example, although MGAT expression 
and activity have been detected in adipose tissue (8, 17), its 
contribution to adipocyte lipid metabolism is unclear.
Because adipose tissue triglyceride synthetic rates are ex-
tremely high and Mogat1 is known to be transcriptionally-
activated by PPAR (13, 14), the master regulator of 
adipogenesis, we sought to test the hypothesis that Mogat1 
is also expressed in adipocytes and regulates adipocyte 
lipid metabolism. We found that Mogat1, which encodes 
the MGAT1 enzyme, is robustly induced in adipocytes 
during the process of adipogenesis. Moreover, Mogat1 ex-
pression is inversely correlated with lipolytic rates, and sup-
pression of Mogat1 expression increases basal lipolytic 
activity. In addition, adipose tissue MOGAT1 expression is 
greater in people with obesity who are metabolically nor-
mal than those who are metabolically abnormal. Together, 
these data suggest that MGAT1 is involved in both triglycer-
ide production and lipolysis, and demonstrate increased 
adipose tissue MOGAT1 expression is associated with meta-
bolic health in people.
MATERIALS AND METHODS
Animals
Male mice were used in all studies. Ob/ob (catalog number 
000632), ob/+, db/db (catalog number 000697), db/+, and 
C57BL/6J (catalog number 000664) mice were obtained from 
Jackson Laboratory (Bar Harbor, ME). All mice were maintained 
on LabDiet 5053. Ob/Ob, control littermates, and C57BL/6J mice 
were sacrificed at 12 weeks of age. db/db and control littermates 
were sacrificed at 14 weeks of age. All animal experiments were 
approved by the Animal Studies Committee of Washington Uni-
versity School of Medicine.
Generation of Adn-Mogat1/ mice
C57BL/6 mouse embryonic stem cells containing a “knockout 
first” allele of Mogat1 were obtained from the Knockout Mouse 
Project (Project ID CSD35789). This construct contains a targeted 
allele of Mogat1 containing inserted cassettes for promoter-driven 
LacZ and Neo cDNAs flanked by frt sites upstream of exon 4 of 
the Mogat1 gene, which is flanked by LoxP sites. Propagated ES 
cells were injected into developing embryos and then implanted 
into pseudopregnant females. Chimeric offspring were mated to 
establish germline transmission. Resulting heterozygous offspring 
were mated with C57BL/6 mice expressing Flp recombinase 
in a global manner (chicken  actin promoter-driven transgenic) 
to remove LacZ and Neo cassettes and generate mice harboring 
the conditional floxed allele (Fig. 5A). Mogat1 floxed mice were 
then crossed with hemizygous C57BL/6 mice expressing Cre under 
the Adiponectin promoter to create Adn-Mogat1 mice. Littermate 
mice not expressing Cre (fl/fl mice) were used as control mice in 
all experiments. All animal experiments were approved by the 
Institutional Animal Care and Use Committee of Washington 
University.
Assessment of plasma metabolites
Nonesterified FFAs were measured using enzymatic assays 
(Wako Diagnostics, Mountain View, CA). Plasma triglyceride and 
cholesterol were measured using Infinity colorimetric assay kits 
(Thermo Fisher Scientific, St. Peters, MO). Plasma insulin was 
measured using an immunoassay (Singulex, Alameda, CA) by the 
Core Laboratory of the Diabetes Research Center at Washington 
University.
Phenomaster metabolic profiling
Indirect calorimetry, energy expenditure, spontaneous activity, 
and food consumption were measured in Phenomaster TSE® 
cages as previously reported (18). Data was measured and col-
lected at 10 min intervals for 24 h. Prior to measurements, mice 
Table 1. Primer sequences used for quantitative real-time PCR
Mouse Genes Primer Sequence (5′-3′)
Atf3 For: CAG ACC CCT GGA GAT GTC AGT
Rev: TTC TTG TTT CGA CAC TTC GCA
Ccl2 For: TTA AAA ACC TGG ATC GGA ACC AA
Rev: GCA TTA GCT TCA GAT TTA CGG GT
Cd68 For: CCT TGA CCT GCT CTC TCT AAG G
Rev: CTG GTA GGT TGA TTG TCG TCT G
F4/80 For: CCT GAT GGT GAG AAA CCT GA
Rev: CCC CAG GAA ACT CCA GAT AA
Fasn For: GTC TGG AAA GCT GAA GGA TCT C
Rev: TGC CTC TGA ACC ACT CAC AC
Grp78 For: ACC CCG AGA ACA CGG TCT T
Rev: GCT GCA CCG AAG GGT CAT T
Il1b For: GTG TGT GAC GTT CCC ATT AGA C
Rev: GTC GTT GCT TGG TTC TCC TT
Il4 For: GGTCTCAACCCCCAGCTAGT
Rev: GCCGATGATCTCTCTCAAGTGAT
Il10 For: GGC GCT GTC ATC GAT TTC TCC CC
Rev: AGC TCT GTC TAG GTC CTG GAG TCC
Mogat1 For: TGG TGC CAG TTT GGT TCC AG
Rev: TGC TCT GAG GTC GGG TTC
Mogat2 For: TGG GAG CGC AGG TTA CAG A
Rev: CAG GTG GCA TAC AGG ACA GA
Pparg For: AAG ACC CAG CTC TAC AAC AGG C
Rev: GCC AAC AGC TTC TCC TTC TCG G
Nos2 For: GGT TTG AAA CTT CTC AGC CAC C
Rev: TTC TCC GTT CTC TTG CAG TTG A
Slc2a4 For: CTG TCG CTG GTT TCT CCA A
Rev: CTG CTC TAA AAG GGA AGG TGT C
Xbp1t For: CAG ACT ACG TGC GCC TCT GC
Rev: CTT CTG GGT AGA CCT CTG GG
Xbp1s For: TCT GCT GAG TCC GCA GCA GG
Rev: CTC TAA GAC TAG AGG CTT GG
36B4 For: GCA GAC AAC GTG GGC TCC AAG CAG AT
Rev: GGT CCT CCT TGG TGA ACA CGA AGC CC
Human Genes Primer Sequence (5′-3′)
FASN For: TGG AAG TCA CCT ATG AAG CCA
Rev: ACG AGT GTC TCG GGG TCT C
MOGAT1 For: AAA GTG TGT CCT ACA TGG TAA GC
Rev: TGA TCC TTC AGG GTT GTC AGT
PPARG For: ATA AAG TCC TTC CCG CTG AC
Rev: CAC CTC TTT GCT CTG CTC CT
SLC2A4 For: GCC CCA CAG AAG GTG ATT GA
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were housed individually and trained for 1 day in metabolic cages 
before metabolic measurements were collected. Mean relative 
VO2 (expressed in ml/kg/min) and respiratory quotient (RQ; cal-
culated as VCO2/VO2) were determined for 24 h.
Body composition measurements
Body composition was determined using an EchoMRI 3-in-1 
instrument (Echo Medical Systems). Free water mass, lean mass, 
and fat mass were all determined on Adn-Mogat1 KO and WT lit-
termates after 10 weeks on standard chow. Free water mass was 
less than 0.1 g for all mice.
Adipocyte differentiation of MEFs, human preadipocytes, 
and 3T3-L1 fibroblasts
Primary mouse embryonic fibroblasts (MEFs) were isolated from 
14-day-old mouse embryos as previously described (19). Human 
subcutaneous preadipoctyes were purchased from Lonza. 3T3-L1 
fibroblasts were obtained from ATCC. Briefly, cells were seeded in 
12-well plates and propagated to confluence. Two days postcon-
fluence, differentiation was initiated using DMEM containing 
10% FBS, 175 nM insulin, 250 nM dexamethasone, and 0.5 mM 
3-isobutyl-1-methylxanthine (IBMX). Two days after initiation, the 
medium was replaced with a maintenance medium (DMEM con-
taining 10% FBS and 175 nM insulin). Fresh maintenance me-
dium was replaced every 2 days thereafter.
siRNA-mediated Mogat1 knockdown in differentiated  
3T3-L1 adipocytes
ON-TARGETplus, SMARTpool siRNA directed against Mogat1 
(siMogat1) and a nontargeting negative control (siControl) were 
purchased from Dharmacon (Lafayette, CO). Day 6, fully differen-
tiated 3T3-L1 adipocytes were transfected with siMogat1 or siCon-
trol reagents with DarmaFECT 1 (Lafayette, CO) according to the 
manufacturer’s protocol. Adipocytes were treated with siRNAs for 
48 h before RNA, protein, or lipolysis assays were performed.
Lipolysis in cultured cells
Fully differentiated adipocytes were used for lipolysis studies. 
Adipocytes were incubated in Krebs-Ringer-bicarbonate HEPES 
buffer, pH 7.4) containing 4 mg/ml fatty acid free BSA and 
2.5 mM glucose (with or without 1 µM isoproterenol) at 37°C for 
2 h. Lipolysis was evaluated by measuring the amount of glycerol 
and FFAs released into the media. Glycerol was determined 
by a glycerol assay kit (Sigma). FFAs were quantified with a 
NEFA kit (Wako Diagnostics) according to the manufacturer’s 
instructions.
Primary adipose tissue explants, lipolysis, and FFA  
re-esterification
Epididymal adipose tissue was harvested, minced under sterile 
conditions, and cultured for 48 h in M199 (Sigma) containing 
insulin (Sigma, 1.5 g/ml) and dexamethasone (Sigma, 25 nM) 
at 37°C in the presence of 5% CO2. Immediately prior to the 
lipolysis assay, tissue pieces were washed to remove insulin and por-
tioned (30–50 mg per well) into 12-well plates containing 0.25 ml 
of assay medium (Krebs-Ringer Buffer, pH 7.4, supplemented 
with fatty acid free BSA (Sigma, 4%), glucose (Sigma, 5 mM), ad-
enosine (Sigma, 200 M), adenosine deaminase (Roche, 1U/
ml), and N6-(L-2-Phenylisopropyl)adenosine (40 nM, Sigma). To 
begin the lipolysis assay, wells were supplemented with an addi-
tional 250 l of assay medium either without (basal) or with 
(stimulated) 0.5 M isoproterenol. The lipolysis assay was con-
ducted at 37°C (5% CO2) for 2 h. Aliquots of conditioned media 
were collected at 1 and 2 h and lipolysis evaluated by measuring 
the amount of glycerol and FFAs released into the media. Glyc-
erol was determined by a glycerol assay kit (Sigma). FFAs were 
quantified with a NEFA kit (Wako Diagnostics) according to the 
manufacturer’s instructions.
The FFA re-esterification rate in primary epididymal adipose 
tissue explants was quantified using the “balance” method de-
scribed by Vaughan (20). This method is based on the following 
Fig. 1. Mogat1 is induced during differentiation of 
mouse and human adipocytes. A: Expression of the 
indicated genes in MEF-derived adipocyte precursor 
cells after 0, 2, 4, 6, or 8 days of culture in differentia-
tion medium as described in the Materials and Meth-
ods. Data are presented as mean ± SEM, n = 5 per 
group, *P < 0.05 versus D0 fibroblasts. B: Expression of 
the indicated genes in human subcutaneous adipocyte 
precursor cells after 0, 2, 4, 6, or 8 days of culture in 
differentiation medium as described in the Materials 
and Methods. Data are presented as mean ± SEM, *P < 
0.05 versus D0 fibroblasts. C: Western blot analysis for 
MGAT1 proteins in 3T3-L1 fibroblasts and differenti-
ated adipocytes (D) MGAT enzymatic activity in 3T3-
L1 fibroblasts or differentiated adipocytes. Data are 
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formula: re-esterified FFA (nmol/mg tissue/hr) = 3 × released 
glycerol (nmole/mg/hr)  released FFA (nmol/mg/hr). The 
formula accounts for total change in both FFA and glycerol in 
the system (media and cell-associated). Glycerol was deter-
mined by a glycerol assay kit (Sigma). FFAs were quantified 
with a NEFA kit (Wako Diagnostics) according to the manufac-
turer’s instructions.
MGAT enzymatic assays
MGAT assays were performed to measure initial activity 
rates as previously described (13). Adipocytes and fibroblasts 
were homogenized in 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 
and 0.25 M sucrose. Monoolein was dried down and reconsti-
tuted in assay buffer containing 5 mM MgCl2, 1.25 mg/ml BSA, 
200 mM sucrose, 100 mM Tris-HCl (pH 7.4), 25 M [14C]oleoyl-
CoA, and 200 M sn-2-oleoylglycerol. Fifty micrograms of pro-
tein were used to initiate each reaction and incubated for 5 
min. The reaction was terminated by the addition of 50 ml 1% 
phosphoric acid. Lipids were extracted with 0.300 ml CHCl3/
MeOH (2:1 vol/vol) and separated by TLC with hexane/ethyl 
ether/acetic acid (80:20:1 vol/vol/vol). Lipids were extracted 
and separated on Linear-K preadsorbent TLC plates. The spots 
corresponding to DG and triacylglycerol were scraped from the 
TLC plates and 14C-radioactivity was quantified by a scintillation 
counter.
mRNA isolation and gene expression analyses
Total adipose tissue RNA was extracted with RNA-BEE (Iso-Tex 
Diagnostics, Friendswood, TX) according to the manufacturer’s 
instructions. First-strand cDNA synthesis was performed using ABI 
reagents, and quantitative real-time RT-PCR was performed using 
the ABI PRISM 7500 sequence detection system (Applied Biosys-
tems, Foster City, CA) with Power SYBR green. Arbitrary units of 
target mRNA were corrected to the corresponding level of the 
36B4 mRNA. The sequences of the primers used in these studies 
are found in Table 1.
Western blot analyses
For Western blot analyses, protein extracts were obtained from 
tissue by using the following lysis buffer containing a protease in-
hibitor cocktail: 10 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM 
EDTA, 0.1% sodium deoxycholate, and 1% Triton X-100. Anti-
body against MGAT1 was generated by Proteintech by using the 
synthetic peptide that corresponds to C-terminal amino acids 322-
335 of mouse MGAT1.
Assessments in human subjects
Subcutaneous abdominal adipose tissue samples obtained 
from 22 men and women with obesity (mean ± SD, BMI 40.6 ± 9.2 
kg/m2), as part of their participation in a previous study that eval-
uated the metabolic effects of weight gain (3), were used to evalu-
ate MOGAT1 and MOGAT2 expression. Adipose tissue samples 
were obtained during the basal period of a hyperinsulinemic-
euglycemic clamp procedure, which was conducted in conjunc-
tion with the infusion of 6,6-2H2]glucose and [U-
13C]palmitate 
tracers (Cambridge Isotope Laboratories) to assess insulin glucose 
rate of disappearance from plasma during basal conditions and 
insulin infusion and FFA rate of appearance in plasma during basal 
conditions, as previously described (3).
Statistical analysis
Statistical comparisons were made using t-test or ANOVA 
where appropriate. Unless specified, all data are presented as 
mean ± SEM, with statistically significant difference defined as 
P < 0.05.
RESULTS
Mogat1 is induced during differentiation of mouse and 
human adipocytes
We evaluated the expression and activity of Mogat1 dur-
ing adipocyte differentiation. Mouse embryonic fibroblasts 
and human subcutaneous preadipocytes were cultured in 
the presence of adipocyte differentiation cocktail, and the 
expression of Mogat1 and MOGAT1 was evaluated as the 
cells differentiated into adipocytes. The expression of both 
Mogat1 and MGAT1 was very low in both fibroblasts and 
preadipocytes, but increased markedly as mouse and hu-
man cells attained their differentiated phenotype (Fig. 1A, B). 
The timing of this induction coincided with an increased 
expression of PPAR (Fig. 1A, B), a master regulator of 
Fig. 2. Mogat1 expression is decreased in adipose tissue of ob/ob 
and db/db mice and suppressed by lipolytic stimuli. A: Expression of 
indicated genes in adipose tissue of ob/+ vs ob/ob. Data are presented 
as mean ± SEM, n = 6 per group, *P < 0.05 versus ob/+ mice. B: Ex-
pression of indicated genes in adipose tissue of db/+ versus db/db 
mice. Data are presented as mean ± SEM, n = 6 per group, 
*P < 0.05 versus ob/+ mice.
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adipocyte differentiation, and the expression of lipin-1, a key 
enzyme in the glycerol-3-phosphate pathway of triglyceride 
synthesis (Fig. 1A, B). Differentiation also caused an in-
crease in the expression of Mogat2 in the mouse adipocytes, 
but this increase was very small (data not shown). MOGAT2 
was undetectable in human adipocytes (data not shown). 
The increase in gene expression of Mogat1 was associated 
with an increase in MGAT1 levels, determined by using 
Western blot analysis (Fig. 1C). In addition, MGAT activity 
was much greater in mature adipocytes than in fibroblasts 
(Fig. 1D), demonstrating that the increased expression of 
Mogat1 results in a functional increase in enzyme activity. 
Together, these data indicate that the expression of 
MGAT1 and MGAT activity is markedly increased during 
adipocyte differentiation.
Mogat1 expression is decreased in adipose tissue of ob/ob  
and db/db mice
We sought to determine whether the expression of 
Mogat1 might be regulated in adipose tissue in mouse mod-
els of metabolically abnormal obesity. Compared with ob/+ 
mice, ob/ob mice had a much lower expression of Mogat1 in 
epididymal adipose tissue (Fig. 2A). Mogat1 expression was 
also markedly decreased in db/db mice compared with db/+ 
mice (Fig. 2B). Consistent with a role for PPAR in regulat-
ing Mogat1, the expression of Pparg was significantly de-
creased in ob/ob as well as db/db mice. Furthermore, the 
expression of other lipogenic genes such as fatty acid syn-
thase (Fasn) and the glucose transporter, Slc2a4 (GLUT4), 
was also significantly lower in the ob/ob and db/db mice than 
in ob/+ and db/+ mice.
Adipose tissue Mogat1 expression is suppressed by 
lipolytic stimuli
We examined the expression of Mogat1 in mice after a 
prolonged (36 h) fast, which is a potent lipolytic stimulus. 
Fasting caused a 90% reduction in the expression of 
Mogat1 in epididymal adipose tissue of C57BL/6J mice 
(Fig. 3A). Upon refeeding for 12 h after a 24 h fast, Mogat1 
expression returned to levels observed in the fed state. The 
expression of Fasn and Slc2a4 was also suppressed in adi-
pose tissue by fasting and restored by refeeding. However, 
Pparg expression was not regulated in parallel. We also as-
sessed the effects of a  agonist (isoproterenol) on Mogat1 
expression. Six hours after administration of isoproterenol, 
Mogat1 expression was markedly decreased in epididymal 
adipose tissue of mice (Fig. 3B). To examine whether these 
effects were direct, we treated 3T3-L1 adipocytes for 24 h 
with isoproterenol or IBMX, which both activate protein 
kinase A and lipolysis. Both isoproterenol and IBMX re-
duced Mogat1 expression (Fig. 3C). In contrast, insulin 
treatment, which inhibits lipolytic activity, resulted in 
increased Mogat1 expression (Fig. 3C). These data demon-
strate a negative relationship between adipocyte lipolytic 
rate and Mogat1 expression.
Mogat1 knockdown increases basal FFA release
To test whether suppressing Mogat1 would affect lipo-
lytic rates, we treated differentiated adipocytes with siRNA 
against Mogat1 (siMogat1) or negative control siRNA 
(siControl). Forty-eight hours later, Mogat1 expression was 
reduced by 90% compared with siControl-treated cells, 
while Mogat2 expression was unaffected by siMogat1 treat-
ment (Fig. 4A). Differentiated 3T3-L1s (treated with the 
siControl or siMogat1 for 48 h) were serum-starved for 4 h 
before measuring basal and -adrenergic stimulated-lipolysis 
(10 M isoproterenol) for 1 h. A 90% reduction in ex-
pression of Mogat1 increased adipocyte FFA release in 
basal conditions (Fig. 4B), but stimulated lipolytic activity 
was not affected. Expression and stimulated phosphoryla-
tion of the adipocyte’s major lipolytic machinery; namely, 
phosphorylated hormone sensitive lipase, phosphory-
lated perilipin 1, and adipose tissue triglyceride lipase, 
was not affected by knockdown of Mogat1 (Fig. 4C), 
suggesting a direct effect of MGAT1 enzymatic activity on 
FFA re-esterification.
Fig. 3. Mogat1 expression is suppressed by lipolytic 
stimuli. A: Expression of indicated genes in adipose 
tissue of mice during fasted conditions and upon 
refeeding. Data are presented as mean ± SEM, n = 6 
per group, *P < 0.05 versus ad libitum (fed). B: Mogat1 
expression in mice following injection of isoprotere-
nol (25 mg/kg IP). Data are presented as mean ± 
SEM, n = 5 per group, *P < 0.05 versus vehicle. C: Mo-
gat1 expression in 3T3-L1 cells treated with insulin 
(100nM), isoproterenol (10M), or isobutylmethylx-
anthine (IBMX, 0.5nM) for 24 h. Data are presented 
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Adipocyte-specific Mogat1 knockout mice have increased 
basal rates of FFA release
To further confirm our in vitro findings of Mogat1 knock-
down, we generated fat-specific Mogat1 knockout mice using 
Cre-LoxP mediated methods (Adn-Mogat1/) (Fig. 5A). 
These mice were viable and did not display an outward 
phenotype at baseline. Adn-Mogat1/ mice had signifi-
cantly decreased expression of Mogat1 in all examined 
fat depots, but expression levels were not altered in the 
stomach or the liver (Fig. 5B). Western blot analysis also 
demonstrated loss of MGAT1 protein in adipose tissue of 
the knockout mice, which was accompanied by decreased 
MGAT activity (Fig. 5C).
At 10 weeks old, male Adn-Mogat1/ mice fed a stan-
dard low fat chow weighed the same as their WT littermates 
(Fig. 5D). To determine total body composition, mice were 
subjected to noninvasive EchoMRI measurements. Adn-
Mogat1/ mice and WT littermates had similar total lean 
mass, but Adn-Mogat1/ mice had significantly less total 
fat mass compared with age-matched littermates (Fig. 5D). 
These measures were confirmed at euthanasia; epididymal 
and inguinal fat pads from the Adn-Mogat1/ mice were 
significantly smaller than control littermates, while the sub-
scapular brown fat pad was not different (Fig. 5E). Interest-
ingly, liver triglyceride levels were not significantly affected, 
but trended lower, in the Adn-Mogat1/ mice (Fig. 5F). 
Blood glucose was significantly decreased in the Adn-
Mogat1/ mice after a 4 h fast (Table 2), whereas plasma 
lipids (triglycerides, FFAs, and cholesterol) were unchanged 
(Table 2). Interestingly, despite having smaller fat pad 
mass, the Adn-Mogat1/ mice did not display significant 
differences in food intake, O2 consumption, CO2 produc-
tion, respiratory exchange ratio, or energy expenditure dur-
ing a 24-h assessment (Table 3).
Lipolytic rates were assessed in isolated adipose tissue ex-
plants from Adn-Mogat1/ mice and matched littermate 
controls. Although isoproterenol-stimulated adipose tissue 
lipolytic rate was not different between groups, the basal 
rate of FFA release from Mogat1 knockout mice was signifi-
cantly increased compared to control mice (Fig. 5G). More-
over, the FFA re-esterification rate was significantly decreased 
in the epididymal fat pads from Adn-Mogat1 mice (Fig. 5H). 
These data are again consistent with adipocyte MGAT1 play-
ing a role in the recycling of FFAs and MG during conditions 
of low lipolytic flux. Interestingly, unlike the previous report 
showing that diacylglycerol acyltransferase (DGAT) defi-
ciency led to increased endoplasmic reticulum stress due to 
the increase in lipolytic products (21), we found no evidence 
for ER stress in fat pads of Adn-Mogat1/ mice and the ex-
pression of some of these genes was actually reduced (Fig. 6).
Adipose tissue biology in people with metabolically-normal 
and metabolically-abnormal obesity
We next sought to determine whether the results from 
the studies conducted in mice apply to humans by evaluat-
ing subcutaneous adipose tissue MOGAT1 expression and 
the relationship between adipose tissue MOGAT1 expres-
sion and basal lipolytic activity in 22 men and women with 
either metabolically-normal obesity (MNO, n = 10) or met-
abolically-abnormal obesity (MAO, n = 12) (Table 4). The 
classification of MNO and MAO was determined by the 
glucose infusion rate required to maintain euglycemia 
during a hyperinsulinemic-euglycemic clamp procedure, 
based on the upper and lower tertile of values we obtained 
in previous studies; those with a glucose infusion rate 10.5 
mg/kg fat-free mass/min were defined as MNO and those 
with a glucose infusion rate 6.9 mg/kg fat-free mass/min 
were defined as MAO. Subjects with MAO had lower subcu-
taneous adipose tissue expression of MOGAT1 than those 
with MNO (Fig. 7A). Adipose tissue MOGAT2 expression 
was undetectable in all subjects (data not shown). In con-
cert with the data obtained in our rodent models of obesity 
Fig. 4. Mogat1 knockdown in differentiated 3T3-L1 adipocytes 
leads to increased basal FFA release. A: Mogat1 knockdown using 
siRNA in differentiated adipocytes. Data are presented as mean ± 
SEM, n = 5 per group, *P < 0.05 versus siControl. B: Mogat1 knock-
down in differentiated adipocytes leads to increased FFA release 
during basal lipolysis, but not isoproterenol stimulated lipolysis. 
Data are presented as mean ± SEM, n = 5 per group, *P < 0.05 ver-
sus siContol. C: Western blots for lipolytic machinery, p-HSL, total 
HSL, p-PLIN, ATGL, and tubulin.
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Fig. 5. Adipocyte-specific Mogat1 knockout mice have increased basal rates of FFA release. A: Breeding Schematic for the creation of Adn-
Mogat1/ mice. B: Mogat1 mRNA expression of profile of Adn-Mogat1 mice and WT littermates. Data are presented as mean ± SEM, n = 6 
per group, *P < 0.05 versus WT littermates. eWAT, epididymal adipose tissue; iWAT, inguinal adipose tissue; sBAT, subscapular brown adipose 
tissue. C: Western blot depicts loss of MGAT1 protein in epididymal fat pads. MGAT activity is reduced in epididymal fat pads from Adn-
Mogat1/ mice. Data are presented as mean ± SEM, n = 5 per group, *P < 0.05 versus WT littermates. D: Body weight and composition of 
10-week-old, chow-fed male Adn-Mogat1 mice and WT littermates. Data are presented as mean ± SEM, n = 9 per group, *P < 0.05 versus WT 
littermates. E: Weight of eWAT, iWAT, and sBAT from 10-week-old, chow-fed Adn-Mogat1 mice and WT littermates. Data are presented as 
mean ± SEM, n = 9 per group, *P < 0.05 versus WT littermates. F: Hepatic triglyceride content for 10-week-old, chow-fed Adn-Mogat1 mice 
and WT littermates. Data are presented as mean ± SEM, n = 9 per group. G: Basal FFA release is increased from epididymal adipose tissue 
fragments from Adn-Mogat1/ mice under basal conditions but not isoproterenol (Iso) stimulated conditions. Data are presented as mean 
± SEM, n = 6 per group, *P < 0.05 versus WT littermates. H: FFA re-esterification rate is reduced in epididymal fat pads from Adn-Mogat1/ 
mice compared with WT littermates. Data are presented as mean ± SEM, n = 5 per group, *P < 0.05 versus WT littermates.
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and insulin resistance, adipose tissue expression of other 
lipogenic genes, including PPARG, FASN, and SLC2A4, was 
lower in subjects with MAO than those with MNO. In addi-
tion, adipose tissue MOGAT1 expression was positively cor-
related with insulin sensitivity, assessed by the rate of 
glucose disposal during a hyperinsulinemic-euglycemic 
clamp procedure (R = 0.59, P = 0.004) (Fig. 7B), and was 
negatively correlated with basal adipose tissue lipolytic ac-
tivity, assessed as the rate of appearance of FFA into the 
bloodstream determined by using a stable isotopically la-
beled palmitate tracer infusion (R = 0.41, P = 0.04) (Fig. 
7C). Overall, these data are consistent with the concept 
that MAO in humans is associated with an impaired expres-
sion of adipose tissue genes encoding factors that promote 
triglyceride storage, and a decrease in adipose tissue 
MOGAT1 expression contributes to an increase in basal 
adipose tissue lipolytic rate.
DISCUSSION
The initial report on cloning of MGAT1 detected its 
expression and activity in adipocytes (8), but very little is 
known about the physiologic role of adipocyte MGAT1 ac-
tivity. Accordingly, we conducted a series of studies in cell 
systems, animal models, and human subjects to explore the 
metabolic function of adipocyte MGAT activity and its rel-
evance in humans. Our data demonstrate that: 1) mice 
lacking Mogat1 in adipocytes have less fat mass than WT 
littermates; 2) adipose tissue expression of Mogat1 is sup-
pressed in response to physiologic stimuli that increase adi-
pose tissue lipolytic activity; 3) loss of Mogat1 in adipocytes 
increases basal lipolytic rate; and 4) adipose tissue MOGAT1 
expression was positively correlated with insulin sensi-
tivity and negatively correlated with adipose tissue lipo-
lytic activity in humans. Together, these data demonstrate 
that adipocyte MGAT activity has important physiological 
functions in preadipocyte differentiation and lipolysis of 
adipocyte triglycerides, and suggest MGAT activity may af-
fect whole body insulin sensitivity.
Our data suggest that Mogat1 is a novel regulator of FFA 
release from adipocytes. By using Mogat1 knockdown and 
adipocyte specific Mogat1 knockout mice, we demonstrated 
that MGAT activity decreased the release of FFAs from adi-
pocytes during basal conditions. We postulate that MGAT 
TABLE 2. Plasma metabolites from 10-week-old male WT and  
Adn-Mogat1/ mice littermates after a 4 h fast 
fl/fl Adn-Mogat1/ P
Glucose (mg/dl) 170 ± 3 155 ± 6 0.045
Insulin (ng/ml) 0.56 ± 0.05 0.69 ± 0.13 0.37
Free fatty acids (M) 0.42 ± 0.03 0.38 ± 0.04 0.17
Triglycerides (mg/dl) 71 ± 6 67 ± 5 0.51
Cholesterol (mg/dl) 78 ± 6 83 ± 5 0.15
n = 9 per group.
TABLE 3. Energy balance and activity of 10-week-old male WT and 
Adn-Mogat1 KO mice fed a chow diet ad libitum over 24 h 
fl/fl Adn-Mogat1/ P
Food intake (g/day) 2.3 ± 0.1 2.2 ± 0.2 0.92
O2 consumption (ml/h/kg) 3143 ± 110 3286 ± 157 0.49
CO2 production (ml/h/kg) 2833 ± 124 2967 ± 162 0.54
Respiratory exchange ratio 0.894 ± 0.008 0.895 ± 0.006 0.92
Energy expenditure (kcal/h/kg) 15.5 ± 0.6 16.2 ± 0.8 0.50
Activity counts 295 ± 32 244 ± 43 0.42
WT, n = 4; KO, n = 4.
Fig. 6. Gene expression of inflammatory markers in WT and Adn-
Mogat1/ mice. Expression of indicated genes in epidydimal adi-
pose tissue of obese human subjects. Data are presented as mean ± 
SEM, n = 6 per group, *P < 0.05.
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TABLE 4. Characteristics of metabolically normal and metabolically 





Sex, n (male/female) 10 (2/8) 12 (2/10)
Age, y 48 ± 10 39 ± 12 0.062
Body mass index 35.1 ± 4.7 43.5 ± 9.3 0.015
Body fat mass, % 45 ± 7 48 ± 7 0.25
IHTG content, % 4.7 ± 3.9 11.6 ± 9.1 0.047
Glucose, mg/dl 97 ± 7 99 ± 9 0.594
Insulin, mU/L 8.9 ± 3.1 22.5 ± 7.0 0.00002
Total-cholesterol, mg/dl 170 ± 39 164 ± 26 0.681
LDL-cholesterol, mg/dl 100 ± 28 103 ± 19 0.795
HDL-cholesterol, mg/dl 48 ± 11 36 ± 6 0.010
Triglyceride, mg/dl 108 ± 58 121 ± 52 0.593
Data are mean ± SD. IHTG, intrahepatic triglyceride.
Fig. 7. Adipose tissue biology in people with meta-
bolically-normal and metabolically-abnormal obesity. 
A: Expression of indicated genes in subcutaneous adi-
pose tissue of obese human subjects. Data are pre-
sented as mean ± SEM, *P < 0.05. B: Subcutaneous 
adipose tissue MOGAT1 expression is positively cor-
related with the whole body glucose disposal rate 
during a hyperinsulinemic euglycemic clamp. C: Sub-
cutaneous adipose tissue MOGAT1 expression is in-
versely correlated with whole body lipolysis before 
hyperinsulinemic euglycemic clamp.
activity promotes FFA re-esterification and this serves to pre-
vent FFA release when lipolytic rates should be low. We did 
not identify other effects on lipolytic machinery expression 
or phosphorylation status after Mogat1 knockdown, suggest-
ing that an important function of MGAT1 is re-esterifying 
the FFAs back into DG to prevent their release. While basal 
lipolysis was increased in the setting of Mogat1 knockdown, 
stimulated lipolysis was not changed. This is not completely 
unexpected and is consistent with our observation that 
there is a significant suppression of Mogat1 expression in 
mouse models associated with high rates of adipose tissue 
lipolytic activity, including fasting, -adrenergic receptor ac-
tivation, and genetic obesity. Together, these findings suggest 
MGAT1 regulates FFA release during both basal and stimu-
lated lipolytic conditions. MGAT1 activity promotes FFA re-
esterification, effectively minimizing FFA release during basal 
lipolytic conditions. However, during stimulated lipolysis, 
MGAT1 expression is diminished to promote maximal FFA 
efflux from adipocytes. In concert with this observation, it 
was recently reported that the final enzyme in the triglyceride 
synthesis pathway, DGAT1, also plays a role in FFA recycling 
of lipolytic products by acylating DG (21). These results 
suggest that these two enzymes work together to oppose 
lipolysis in adipocytes.
Although obesity is typically associated with a constella-
tion of metabolic abnormalities, including insulin resis-
tance and dyslipidemia, not all people with obesity become 
insulin resistant. Lipid dynamics in adipose tissue may pro-
vide an explanation for the differences in the individuals 
with MNO versus MAO. Indeed, it has been shown that a 
high capacity for both glucose uptake and de novo lipogen-
esis in adipose tissue is metabolically protective in people 
with MNO. On the other hand, individuals with obesity- 
related metabolic syndrome or insulin resistance have been 
found to have a reduced capacity in adipose tissue to take 
up glucose and synthesize FAs from carbohydrates. In the 
present study, people with MAO had significantly lower ex-
pression of PPARG, FASN, and SLC2A4, which is consistent 
with previous reports in adipose tissue of people with MAO. 
We also found a significant decrease in MOGAT1 expression 
in individuals with MAO compared with those with MNO, 
suggesting that individuals with MAO also have diminished 
capacity for triglyceride synthesis in adipose tissue. While 
the sample size is small, we found MOGAT1 expression in 
adipose tissue is positively correlated with insulin sensitivity 
and negatively correlated with basal FFA rates of release 
into the circulation, assessed by using the hyperinsulinemic-
euglycemic clamp procedure. Furthermore, in insulin resis-
tant people, the downregulation of MOGAT1 in adipose 
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tissue may contributes to decreased FFA re-esterification 
and increased FFA release in the blood stream. Indeed, in-
sulin resistance is associated with increased basal lipolytic 
rate and the generation of FFAs (22–24), while partial inhi-
bition of adipose tissue lipolysis can improve glucose me-
tabolism and insulin sensitivity (25–28). However, we did 
not detect evidence of insulin resistance in Adn-Mogat1/ 
mice, which had less fat mass and lower blood glucose than 
WT controls. This will need to be examined more thor-
oughly and under conditions where obesity is promoted.
We found that deletion of MGAT1 in adipocytes led to a 
substantial reduction in MGAT enzymatic activity. These 
results indicate that MGAT1 protein contributes to overall 
MGAT activity in adipose tissue. Our findings are contra-
dictory to those from a recent study conducted in a whole 
body Mogat1 knockout mouse (16). That study found there 
were no deficits in tissue MGAT activity in global Mogat1/ 
mice. However, MGAT activity was undetectable in many 
tissues that were examined. It is possible the inability to 
detect any changes in MGAT activity could be due to com-
pensation by MGAT2. Additional studies are necessary to 
address these discrepancies.
In summary, we demonstrate that Mogat1 is robustly in-
duced during adipocyte differentiation and expression of 
adipose tissue Mogat1 in mice and MOGAT1 in humans are 
suppressed in states of relative insulin resistance and in-
creased lipolytic rates. In addition, our data demonstrate 
MOGAT1 is likely involved in regulating FFA re-esterification 
into triglyceride and therefore FFA release from adipose tis-
sue. These data collectively demonstrate a novel role for 
MGAT activity in regulating adipocyte lipid homeostasis with 
potential relevance for our understanding of the physiologic 
process of lipolysis and the pathophysiology of obesity.
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